Over the past 3 decades, monoclonal antibodies and their related derivatives, including recently approved antibody-drug conjugates, conquered a central role in cancer therapy because of their contribution to improve survival, time to progression and quality of life of patients compared to chemotherapy protocols. This review summarizes information on approved original and biosimilar products, as well as investigational antibody-based therapeutics, targeting ErbB2. This target has been selected as a paradigmatic example because of its relevant role in sustaining the malignancy of major cancer diseases including, breast, gastric and other chemotherapy-resistant solid tumors. This work analyzes the drivers affecting research and development of next-generation anti-ErbB2 immunotherapeutics, taking into account unmet medical needs and pharmacoeconomic issues related to sustainability. The analysis may help with the design of future research and development strategies.

中文翻译：

---

抗ErbB2免疫疗法：努力为癌症疗法制造更好的抗体。

在过去的30年中，单克隆抗体及其相关衍生物（包括最近批准的抗体-药物缀合物）在癌症治疗中占据了中心地位，因为与化学疗法相比，单克隆抗体及其相关的衍生物可改善患者的生存率，进展时间和生活质量。这篇综述总结了针对ErbB2的已批准原始和生物仿制药产品以及基于抗体的研究性治疗药物的信息。选择该靶点作为范例是因为其在维持主要癌症疾病（包括乳腺癌，胃癌和其他对化疗有抵抗力的实体瘤）的恶性肿瘤中的相关作用。这项工作分析了影响下一代抗ErbB2免疫疗法研发的驱动因素，考虑到未满足的医疗需求和与可持续性相关的药物经济学问题。该分析可能有助于设计未来的研究和开发策略。